ФОСЕР Линетт А. (US),ХИДЖИН Мартин (US),ЛЮКСЕНБЕРГ Дебора П. (US),О'ТУЛ Марго (US),ОТУЛ Марго (US)
申请号：
RU2011144166/15
公开号：
RU2011144166A
申请日:
2011.11.01
申请国别(地区):
RU
年份:
2013
代理人:
摘要：
1. A method of treating atopic dermatitis in a subject, comprising administering to said subject an antibody or an antigen binding fragment thereof binding to human IL-22, said antibody or antigen binding fragment thereof comprising (a) domain V, which contains at least 90 amino acid sequence % identical to the amino acid sequence of SEQ ID NO: 59, and domain V, which contains the amino acid sequence, at least 90% identical to the amino acid sequence of SEQ ID NO: 60； (b) domain V, which contains the last successive amino acids, at least 90% identical to the amino acid sequence of SEQ ID NO: 95, and domain V, which comprises an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 96.2. The method according to claim 1, characterized in that a) the V domain contains the amino acid sequence of SEQ ID NO: 617 and the V domain contains the amino acid sequence of SEQ ID NO: 618； b) the V domain contains the amino acid sequence of SEQ ID NO: 618 and the V domain contains the amino acid sequence of SEQ ID NO : 492； c) the V domain contains the amino acid sequence of SEQ ID NO: 167 and the V domain contains the amino acid sequence of SEQ ID NO: 168； d) the V domain contains the amino acid sequence of SEQ ID NO: 185 and the V domain contains the amino acid sequence of SEQ ID NO: 186； or e) the V domain contains the amino acid sequence of SEQ ID NO: 203 and the V domain contains the amino acid sequence of SEQ ID NO: 204.3. The method according to claim 1, characterized in that a) the V domain contains the amino acid sequence of SEQ ID NO: 347 and the V domain contains the amino acid sequence of SEQ ID NO: 348； b) the V domain contains the amino acid sequence of SEQ ID NO: 311 and the V domain contains the sequence�1. Способ лечения атопического дерматита у субъекта, включающий введение указанному субъекту антитела или его антигенсвязывающего фрагмента, связывающегося с IL-22 человека, причем указанное антитело или его антигенсвязывающий фрагмент
